Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

HC Andersen Capital: Pharma Equity Group - Lifescience investment company with twofold strategy

Pharma Equity Group

The investment case is driven by PEG's ability to successfully implement and follow a twofold strategy: firstly, to create value by traditional medical development of the pipeline of projects for the individual indications in Reponex. Secondly, to create value via its unique repositioning and reformulation strategy, where already established medical formulas are being used to find new indications, new ways of delivery mechanisms, or new combinations with other established products. The idea is to utilize already available data regarding efficacy, toxicity, and safety, saving both time and money to bring products to market.

Read the full one-pager here. (https://www.inderes.dk/research/initiation-1-pager)

This is a press release from HC ANDERSEN CAPITAL www.hcandersencapital.dk.

Disclaimer: HC Andersen Capital receives payment from Pharma Equity Group for a Digital IR / Corporate Visibility subscription agreement.

HC ANDERSEN CAPITAL
Claus Thestrup,
CEO Sweden
claus@hcandersencapital.dk

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.